A Study of LUCAR-20SP in Subjects with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-20SP, an Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy Targeting CD20 in Subjects with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yuqin Song
- Phone Number: 13683398726
- Email: songyq22622@163.com
Study Contact Backup
- Name: Yan Xie
- Phone Number: 13671376201
- Email: xieyan9@263.net
Study Locations
-
-
-
Zhengzhou, China
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Keshu Zhou
- Phone Number: 13674902391
- Email: drzhouks77@163.com
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Peking University Cancer Hospital & Institute
-
Contact:
- Yuqin Song
- Phone Number: 13683398726
- Email: songyq22622@163.com
-
Contact:
- Yan Xie
- Phone Number: 13671376201
- Email: xieyan9@263.net
-
Contact:
- Yuqin Song
-
Beijing, Beijing, China, 100070
- Recruiting
- Beijing GoBroad Boren Hospital
-
Contact:
- Yajing Zhang
- Phone Number: 18501333856
- Email: zhangyj3@gobroadhealthcare.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects voluntarily participate in clinical research;
- Age ≥18 years old;
- Eastern Cooperative Oncology Group (ECOG) score 0-1;
- Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, histologically indolent lymphoma to diffuse large B-cell lymphoma; CD20 positive;
- At least one measurable tumor lesion according to the Lugano 2014.
- Expected survival ≥3 months;
- Clinical laboratory values in the screening period meet criteria.
- Effective contraception.
Exclusion Criteria:
- Prior antitumor therapy with insufficient washout period.
- Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection;
- Previously received allogeneic hematopoietic stem cell transplantation;
- Previously received gene therapy;
- Donor specific antibody (DSA) positive subjects will be excluded;
- Severe underlying diseases;
- Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive;
- Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Each subject will receive LUCAR-20SP cells
Chimeric antigen receptor T cells LUCAR-20SP cells
|
Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose-limiting toxicity (DLT) rate
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
DLT refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Incidence, severity, and type of treatment-emergent adverse events (TEAEs)
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Recommended Phase 2 Dose (RP2D) regimen finding
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
RP2D established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Pharmacokinetics in peripheral blood
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
CAR transgene levels in peripheral blood after LUCAR-20SP infusion.
CAR positive T cells levels in bone marrow after LUCAR-20SP infusion.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Pharmacokinetics in bone marrow
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
CAR positive T cells levels in bone marrow after LUCAR-20SP infusion.
CAR transgene levels in bone marrow after LUCAR-20SP infusion.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR) after administration
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
ORR is defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) after treatment via LUCAR-20SP cell infusion, and the objective tumor response rate will be calculated for patients with measurable disease per the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma (Lugano 2014)
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Time to Response (TTR) after administration
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
TTR is defined as the time from the date of first infusion of LUCAR-20SP to the date of the first response evaluation of the subject who has met all criteria for PR or better.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Duration of Remission (DoR) after administration
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
DoR is defined as the time from the first documentation of remission (PR or better) to the first documented disease progression evidence (according to Lugano 2014) of the responders (who achieve PR or better response).
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
|
Progression-free Survival (PFS) after administration
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)]
|
PFS is defined as the time from the date of first infusion of the LUCAR-20SP to the first documented disease progression (according to Lugano 2014) or death (due to any cause), whichever occurs first.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)]
|
|
Overall Survival (OS) after administration
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)]
|
OS is defined as the time from the date of first infusion of LUCAR-20SP to death of the subject.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)]
|
|
Incidence of anti-LUCAR-20SP antibody
Time Frame: Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
The incidence of anti-LUCAR-20SP antibody in patients who received LUCAR-20SP infusion.
|
Minimum 2 years after LUCAR-20SP infusion (Day 1)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LB2302-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.